The FDA has cleared HuidaGene Therapeutics' investigational new drug application for HG202, the first CRISPR-Cas13 RNA-editing therapy to enter...

In this clinical update, we bring you the latest news from four gene-editing trials sponsored by RenJi Hospital (Shanghai), The University of Texas MD...

In this brief update, we bring you the latest news from three gene-editing clinical trials sponsored by Cellectis, Intellia Therapeutics and Caribou...

Intellia Therapeutics shares interim clinical results from the Phase 1 portion of the ongoing Phase 1/2 trial of NTLA-2002 in hereditary angioedema...

This update shares news about recent designations awarded by the US FDA and European Medicines Agency for gene-editing candidates for the treatment of...

Intellia Therapeutics recently shared new positive clinical data from the ongoing Phase 1 trial of NTLA-2002 in hereditary angioedema (HAE). NTLA-2002...

Intellia Therapeutics recently announced that the FDA has cleared an Investigational New Drug application for NTLA-2002, a single-dose in vivo CRISPR...

In this week's clinical trial update, we summarise the ongoing in vivo CRISPR clinical trials for three distinct rare genetic diseases: hereditary...